Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending June 2014. The report serves as a notification of transactions involving Persons Discharging Managerial Responsibility (PDMRs) under the GlaxoSmithKline Deferred Investment Award programme, executed on June 12, 2014.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding executive compensation awards rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported in this filing. The document details the granting of notional Ordinary Shares to specific PDMRs, with vesting schedules extending from 2016 to 2019.
Guidance, Outlook, and Risks
The filing contains no management guidance, outlook, or discussion of risks and contingencies. It notes that awards are subject to vesting conditions, specifically that the individual must not have served notice or been terminated for cause. Awards are paid in cash upon vesting, including accrued notional dividends.
Important Facts for Investors
- Award Date: June 12, 2014.
- Valuation Basis: Awards were determined using an Ordinary Share price of £16.1625 (average of high and low on the London Stock Exchange on June 12, 2014).
- Recipients: Roger Connor, Abbas Hussain, David Redfern, Claire Thomas, Patrick Vallance, and Emma Walmsley.
- Executive Exclusion: Executive Directors are not eligible for awards under this specific programme.
- Payment Method: Awards and accrued dividends are paid in cash upon vesting, not in shares.